Get the Stockscreener App
26.99
3.33%
-0.9323
Rapport Therapeutics Inc stock is traded at $26.99, with a volume of 71,899.
It is down -3.33% in the last 24 hours and down -11.86% over the past month.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
See More
Previous Close:
$27.92
Open:
$27.82
24h Volume:
71,899
Relative Volume:
0.19
Market Cap:
$1.29B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.67%
1M Performance:
-11.86%
6M Performance:
+74.13%
1Y Performance:
+89.14%
1-Day Range:
$26.98
$28.41
1-Week Range:
$25.66
$28.41
52-Week Range:
$7.13
$42.27
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Name
Rapport Therapeutics Inc
Sector
Industry
Phone
857-321-8020
Address
99 HIGH STREET, BOSTON
Compare RAPP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
26.98 | 1.33B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.63 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Sep-16-25 | Initiated | Truist | Buy |
| Aug-06-25 | Initiated | H.C. Wainwright | Buy |
| Apr-08-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-02-24 | Initiated | Jefferies | Buy |
| Jul-02-24 | Initiated | Stifel | Buy |
| Jul-02-24 | Initiated | TD Cowen | Buy |
View All
Rapport Therapeutics Inc Stock (RAPP) Latest News
Rapport Therapeutics, Inc. (RAPP): Investor Outlook With An 87% Potential Upside - DirectorsTalk Interviews
Abraham Ceesay Sells 5,833 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock - MarketBeat
Rapport Therapeutics CEO Ceesay sells $285k in shares By Investing.com - Investing.com Nigeria
Rapport Therapeutics CEO Ceesay sells $285k in shares - Investing.com
Short Interest in Rapport Therapeutics, Inc. (NASDAQ:RAPP) Expands By 20.7% - Defense World
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Short Interest Up 20.7% in December - MarketBeat
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
David Bredt Sells 8,500 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock - Defense World
Rapport Therapeutics (RAPP) Is Down 7.4% After Advancing RAP-219 Toward Phase 3 In Epilepsy - Sahm
Rapport Therapeutics (NASDAQ:RAPP) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Discipline and Rules-Based Execution in RAPP Response - Stock Traders Daily
Insider Sell: David Bredt Sells 8,500 Shares of Rapport Therapeu - GuruFocus
Rapport Therapeutics (NASDAQ:RAPP) Insider David Bredt Sells 8,500 Shares - MarketBeat
Breakout Zone: Is Rapport Therapeutics Inc gaining market shareWeekly Stock Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: A Biotech With 94.53% Potential Upside - DirectorsTalk Interviews
A Look At Rapport Therapeutics (RAPP) Valuation After FDA Clears Phase 3 Trial For RAP-219 - Sahm
Rapport Therapeutics (NASDAQ:RAPP) Trading Down 6.9%Time to Sell? - MarketBeat
FDA Phase 3 Green Light for RAP-219 Might Change The Case For Investing In Rapport Therapeutics (RAPP) - Sahm
Will Rapport Therapeutics Inc. stock outperform growth indexesJuly 2025 Sector Moves & Safe Capital Growth Tips - Улправда
Rapport Therapeutics, Inc. (RAPP): Investor Outlook with a Promising 84.56% Potential Upside - DirectorsTalk Interviews
Is Rapport Therapeutics Inc. stock a smart buy before Fed meeting2025 Sector Review & Free Expert Approved Momentum Trade Ideas - ulpravda.ru
Can Rapport Therapeutics Inc. stock resist market sell offsQuarterly Portfolio Review & Risk Managed Investment Entry Signals - ulpravda.ru
Form 8-KCurrent report - ADVFN
Rapport Therapeutics (RAPP) Refocuses Neurology Pipeline After RAP-219 Phase 3 Greenlight – What’s the R&D Tradeoff? - Yahoo Finance
A Quick Look at Today's Ratings for Rapport Therapeutics(RAPP.US), With a Forecast Between $40 to $56 - 富途牛牛
Rapport Therapeutics: Accelerated RAP-219 Epilepsy Path to Phase 3 and Strategic Pipeline Refocus Support Buy Rating - TipRanks
Rapport Therapeutics: Diversified Neurology Pipeline and Accelerated RAP-219 Development Underpin Buy Rating - TipRanks
Citizens reiterates Market Outperform rating on Rapport Therapeutics stock By Investing.com - Investing.com Canada
Rapport Therapeutics (RAPP) Receives FDA Clearance to Advance RAP-219 into Phase 3 Trials - Intellectia AI
Rapport To Advance Phase 3 Program Of RAP-219 In Focal Onset Seizures In Q2 - Nasdaq
Los Angeles Daily NewsRapport Therapeutics, Inc.Common Stock (Nasdaq:RAPP) Stock Quote - FinancialContent
Assessing Rapport Therapeutics (RAPP) Valuation After Recent Share Price Strength - Yahoo Finance
Rapport Therapeutics, Inc.Common Stock (NQ: RAPP - FinancialContent
Upcoming EventsRapport Therapeutics, Inc.Common Stock (Nasdaq:RAPP) Stock Quote - FinancialContent
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 7.8%Here's Why - MarketBeat
Have Rapport Therapeutics Insiders Been Selling Stock? - simplywall.st
Form 424B5 Rapport Therapeutics, - StreetInsider
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Program - TradingView — Track All Markets
Rapport Therapeutics Advances RAP-219 into Phase 3 Trials for Focal Onset Seizures, Expands Epilepsy Portfolio with New Program - Quiver Quantitative
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline - GlobeNewswire
What technical charts say about Rapport Therapeutics Inc. stock2026 world cup usa national team qualification goalkeepers possession football odds analysis preview - ulpravda.ru
Rapport Therapeutics (NASDAQ:RAPP) Insider Krishnaswamy Yeleswaram Sells 2,840 Shares - Defense World
Behavioral Patterns of RAPP and Institutional Flows - Stock Traders Daily
Krishnaswamy Yeleswaram Sells 2,840 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Insider Sells $197,338.35 in Stock - MarketBeat
Is Rapport Therapeutics Inc a good long term investmentSupport Level Holds & Free Discover Fast Growing Stocks - earlytimes.in
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 7.2%Here's What Happened - MarketBeat
Rapport Therapeutics, Inc. (RAPP): Investor Outlook with a 72% Potential Upside Amid Strong Buy Ratings - DirectorsTalk Interviews
Guidance Update: Will Rapport Therapeutics Inc stock continue dividend increasesBull Run & AI Optimized Trade Strategies - moha.gov.vn
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Rapport Therapeutics Inc Stock (RAPP) Financials Data
There is no financial data for Rapport Therapeutics Inc (RAPP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Rapport Therapeutics Inc Stock (RAPP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ceesay Abraham | Chief Executive Officer |
Jan 20 '26 |
Sale |
26.11 |
5,083 |
132,737 |
25,812 |
| Bredt David | Chief Scientific Officer |
Jan 15 '26 |
Sale |
26.84 |
8,500 |
228,132 |
395,575 |
4.38%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):